Tidal Investments LLC Acquires 29,283 Shares of Sanofi $SNY

Key Points

• Tidal Investments increased its Sanofi stake by 21.5% in the second quarter, acquiring 29,283 additional shares and bringing its holdings to 165,289 shares valued at approximately $7.05 million.
• Analyst sentiment remains mixed, with ratings ranging from Strong Buy to Sell; the consensus rating is Hold, with an average price target of $49.50.
• Sanofi reported quarterly revenue of $13.36 billion, up 16% year over year, alongside earnings of $2.41 per share. Shares opened at $42.77, near the lower end of their 12-month range.

Tidal Investments LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 21.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 165,289 shares of the company's stock after buying an additional 29,283 shares during the quarter. Tidal Investments LLC's holdings in Sanofi were worth $7,051,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Physician Wealth Advisors Inc. boosted its stake in Sanofi by 180.5% in the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company's stock valued at $28,000 after acquiring an additional 379 shares during the last quarter. Leonteq Securities AG grew its holdings in Sanofi by 95.8% during the 1st quarter. Leonteq Securities AG now owns 607 shares of the company's stock worth $29,000 after acquiring an additional 297 shares during the period. Western Wealth Management LLC bought a new stake in shares of Sanofi during the 1st quarter valued at $29,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Sanofi during the 3rd quarter valued at $29,000. Finally, Palisade Asset Management LLC acquired a new position in shares of Sanofi in the 3rd quarter valued at $30,000. 14.03% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on SNY shares. Royal Bank Of Canada started coverage on Sanofi in a research report on Tuesday. They issued a "sector perform" rating on the stock. Weiss Ratings downgraded Sanofi from a "hold (c-)" rating to a "sell (d)" rating in a report on Monday, August 3rd. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 29th. Morgan Stanley set a $49.00 target price on Sanofi in a report on Wednesday, July 8th. Finally, HSBC restated a "buy" rating on shares of Sanofi in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $49.50.

Sanofi Price Performance

Shares of SNY stock opened at $42.77 on Friday. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. Sanofi has a 12-month low of $40.89 and a 12-month high of $52.68. The firm has a fifty day moving average of $43.95 and a 200-day moving average of $44.58. The firm has a market capitalization of $103.69 billion, a price-to-earnings ratio of 22.39, a price-to-earnings-growth ratio of 1.29 and a beta of 0.35.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $2.41 earnings per share for the quarter. The firm had revenue of $13.36 billion for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The business's quarterly revenue was up 16.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.24 EPS. On average, equities research analysts forecast that Sanofi will post 5.07 earnings per share for the current year.

Sanofi Company Profile

Sanofi is a global healthcare company headquartered in France that develops, manufactures and markets prescription medicines and vaccines. Its portfolio serves patients across areas including immunology, rare diseases, rare blood disorders, neurology, oncology and inflammatory conditions, as well as other specialty-care and general-medicine categories.

The company is also a major vaccine producer through its vaccines business, which supplies products for diseases such as influenza, polio, pertussis, meningitis and dengue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.